43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O

作者：Fabian Trillsch, Aikou Okamoto, JW Kim, A. Reuss, Maria Jesus Rubio Pérez, Mehmet Ali Vardar, V. Salutari, Jean‐Sébastien Frenel, Henna Kärkkäinen, N. Colombo, Anita Monika Chudecka-Glaz, Peter Oppelt, S. Lheureux, Caroline Lamot, Tobias Engler, Robert Michael Wenham, Shin Nishio, A. Correa, P. Harter, Carol A Aghajanian · 发表于：ESMO Open · 年份：2024 · DOI：10.1016/j.esmoop.2024.103550 · 被引用次数：15 · 研究领域：PARP inhibition in cancer therapy、Ovarian cancer diagnosis and treatment、Prostate Cancer Treatment and Research

mtx) for newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm): Updated results from DUO-O